Abstract
Iodine-131 metaiodobenzylguanidine (131I-MIBG), a radiopharmaceutical agent used for scintigraphic localization of pheochromocytomas, has been employed to treat malignant pheochromocytomas since 1983 in a few specialized centers around the world. We review our clinical experience together with the published experience of 23 other centers in 10 countries, regarding the use of 131I-MIBG for treating patients with malignant adrenal pheochromocytomas or extra-adrenal paragangliomas. There were a total of 116 evaluable patients: 3 were from our current report and another 113 were reported in the literature from 1983 to 1996. A majority of the patients were selected for treatment based upon positive tracer uptake studies. The cumulative dose of 131I-MIBG administered ranged from 96 to 2,322 mCi (3.6 to 85.9 GBq), with a mean (±SD) of 490±350 mCi (18.1 ±13.0 GBq). The subjects received a mean single therapy dose of 158 mCi (5.8 GBq) and the number of doses administered ranged from 1 to 11, with a mean of 3.3±2.2 doses. Initial symptomatic improvement was achieved in 76% of patients, tumor responses in 30%, and hormonal responses in 45%. Five patients had complete tumor and hormonal responses, ranging from 16 to 58 months, which were sustained at the time of reporting. Patients with metastases to soft tissue had more favorable responses to treatment than those with metastases to bone. No difference was noted in the age between the responders and non-responders. Adverse effects, recorded in 41 % of the treated patients, were generally mild except for one fatality from bone marrow aplasia. Among 89 patients with follow-up data, 45% of the responders had relapsed with recurrent or progressive disease after a mean interval of 29.3±31.1 months (median 19 months). Of patients with an initial response to 131I-MIBG, death was reported in 33% after a mean of 23.2±8.1 months (median 22 months) following treatment. Of non-responders, death was reported in 45% after a mean of 14.3±8.3 months (median 13 months). In conclusion, this review suggests that 131I-MIBG therapy may be a useful palliative adjunct in selected patients with malignant pheochromocytoma or paraganglioma. Although controlled studies are lacking, our review raises the hope that this therapeutic modality may prolong survival with an occasional sustained complete remission or possible cure.
Similar content being viewed by others
References
Van Heerden J.A., Sheps S.G., Hamberger B., Sheedy P.F., Poston J.G., Remine W.H. Pheochromocytoma: current status and changing trends. Surgery. 91: 367, 1982.
Mahoney E.M., Harrison J.H. Malignant pheochromocytoma: clinical course and treatment. J.Urol. 118: 225, 1977.
Drasin H. Treatment of malignant pheochromocytoma. West. J. Med. 128: 106, 1978.
Robinson R.G., DeQuattro V., Grushkin C.M., Lieberman E. Childhood pheochromocytoma: treatment with alpha methyltyrosine for resistant hypertension. J. Pediatr. 91: 143, 1977.
Scott H.W., Reynolds V., Green N., Page D., Oates J.A., Robertson D., Roberts S. Clinical experience with malignant pheochromocytoma. Surg. Gyneco. I Obstet. 154: 801, 1982.
Keiser H.R., Goldstein D.S., Wade J.L., Douglas F.L., Averbuch S.D. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 7(Suppl I): 1–18, 1985.
Lewi H.J.E., Reid R., Mucci B., Davidson J.K., Kyle K.F., MacPherson S.G., Semple P., Kaye S. Malignant phaeochromocytoma. Br. J. Urol. 57: 394, 1985.
Averbuch S.D., Steakley C.S., Young R.C., Gelmann E.P., Goldstein D.S., Stull R., Keiser H.R. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann. Intern. Med. 109: 267, 1988.
Sisson J.C., Frager M.S., Valk T.W., Gross M.D., Swanson D.P., Wieland D.M., Tobes M.C., Beierwaltes W.H., Thompson N.W. Scintigraphic localization of pheochromocytoma. N. Engl.J. Med. 305: 12, 1981.
Sisson J., Shapiro B., Beierwaltes W.H., Nakajo M., Glowniak J., Mangner T., Carey J.E., Swanson D.P., Copp J., Satterlee W., Wieland D. Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans. Assoc. Am. Physicians. 96: 209, 1983.
Sisson J.C., Shapiro B., Beierwaltes W.H., Glowniak J.V., Nakajo M., Mangner T.J., Carey J.E., Swanson D.P., Copp J.E., Satterlee W.G., Wieland D.M. Radiopharmaceutical treatment of malignant pheochromocytoma. J. Nucl. Med. 24: 197, 1984.
Sisson J.C., Wieland D.M. Radiolabelled meta-iodobenzylguanidine: pharmacology and clinical studies. Am. J. Physiol. Imaging 1: 96, 1986.
Thompson N.M., Allo M.D., Shapiro B., Sisson J.C., Beierwaltes W. Extra-adrenal and metastatic pheochromocytoma: the role of 131I meta-iodobenzylguanidine in localization and management. World J.Surg. 8: 605; 1984.
Shapiro B., Sisson J.C., Eyre P., Copp J.E., Dmuchowski C., Beierwaltes W.H. 131I-MIBG — a new agent in diagnosis and treatment of pheochromocytoma. Cardiology. 72(Suppl I): 137, 1985.
Khafagi F.A., Shapiro B., Fischer M., Sisson J.C., Hutchinson R., Beierwaltes W.H. Pheochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine. Eur. J. Nuc. Med. 18: 191, 1991.
Krempf M., Lumbroso J., Mornex R., Brendel A.J., Wemeau J.L., Delisle M.J., Aubert B., Carpentier P., Fleury-Goyon M.C., Gibold C., Guyot M., Lahneche B., Marchandise X., Schlumberger M., Charbonnel B., Chatal J.F. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J. Clin. Endocrinol. Metab. 72: 455, 1991.
Krempf M., Lumbroso J., Mornex R., Brendel A.J., Wemeau J.L., Delisle M.J., Aubert B., Carpentier P., Fleury-Goyon M.C., Gibold C., Guyot M., Lahneche B., Marchandise X., Schlumberger M., Charbonnel B., Chatal J.F. Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: a French multicenter study. J. Nucl. Biol. Med. 35: 284, 1991.
Mornex R., Badet C., Peyrin L. Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990. J. Endocrinol. Invest. 15: 643, 1992.
Brendel A.J., Jeandot R., Guyot M., Lambert B., Drouillard J. Radionuclide therapy of pheochromocytomas and neuroblastomas using iodine-131 metaiodobenzylguanidine (MIBG). Clin. Nucl. Med. 14: 19, 1989.
Schlumberger M., Gicquel C., Lumbroso J., Tenenbaum F., Comoy E., Bosq J., Fonseca E., Ghillani P.P., Aubert B., Travagli J.P., Gardet P., Parmentier C. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J. Endocrinol. Invest. 15: 631, 1992.
Schvartz C., Gibold C., Vuillemin B., Delisle M.J. Results of [131I]metaiodobenzylguanidine therapy administered to three patients with malignant pheochromocytoma. J. Nucl. Biol. Med. 35: 305, 1991.
Pujol P., Bringer J., Faurous P., Jaffiol C. Metastatic pheochromocytoma with a long-term response after iodine-131 metaiodobenzylguanidine therapy. Eur. J. Nucl. Med. 22: 382, 1995.
Fisher M. Therapy of pheochromocytoma with [131 I]metaiodobenzylguanidine. J. Nucl. Biol. Med. 35: 292, 1991.
Vetter H., Fischer M., Muller-Rensing R., Vetter W., Winterberg B. [131I]-meta-iodobenzylguanidine in treatment of malignant pheochromocytomas. Lancet. 2: 107, 1983.
Lewington V.J., Zivanovic M.A., Tristam M., McEwan A.J.B., Ackery D.M. Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma. J. Nucl. Biol. Med. 35: 280, 1991.
Bomanji J., Britton K.E., Ur E., Hawkins L., Grossman A.B., Besser G.M. Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine. Nucl. Med. Commun. 14: 856, 1993.
Bestagno M., Pizzocaro C., Maira G., Terzi A., Panarotto M.B., Guerra P. Results of [131I]metaiodobenzylguanidine treatment in metastatic malignant phaeochromocytoma. J. Nucl. Biol. Med. 35: 277, 1991.
Trocone L., Rufini V., Montemaggi P., Danza F.M., Lasorella A., Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine. Eur. J. Nucl. Med. 16: 325, 1990.
Trocone L., Rufini V., Daidone M.S., De Santis M., Luzi S. [131I]metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group. J. Nucl. Biol. Med. 35: 295, 1991.
Colombo L., Lomuscio G., Vignati A., Dottorini M.E. Preliminary results of [131I]metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma. J. Nucl. Biol. Med. 35: 300, 1991.
Limone P., Pogliano G., Castellano G., Argiro G., Isaia G.C., Favero A., Cottino F., Rizzi G., Molinatti G.M. 131-I-meta-iodobenzylguanidine for the diagnosis and treatment of pheochromocytoma. Panminerva Med. 30: 169, 1988.
Hoefnagel C.A., Voute P.A., de Kraker J., Marcuse H.R. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J.Nucl. Med. 28: 308, 1987.
Voute P.A., Hoefnagel C.A., de Kraker J., Evans A.E., Hayes A., Green A. Radionuclide therapy of neural crest tumors. Med. Pediatr. Oncol. 15: 192, 1987.
Konings J.E., Bruning P.F., Abeling N.G.G.M., van Gennip A.H., Hoefnagel C.A. Diagnosis and treatment of malignant pheochromocytoma with 1311-meta-iodobenzylguanidine: a case report. Radiother. Oncol. 17: 103, 1990.
Hoefnagel C.A., Schornagel J., Valdes Olmos R.A. [131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J. Nucl. Biol. Med. 35: 308, 1991.
Goncalves E., Ninane J., Wese F.X., Leonet J., Piret L., Cornu G., De Meyer R. Familial phaeochromocytoma: successful treatment with 131I-MIBG. Med. Pediatr. Oncol. 18: 126, 1990.
Theilade K., Bak M., Olsen K., Nielsen S.L., Christensen N.J. A case of malignant pheochromocytoma treated by 131 I-metaiodobenzylguanidine. Acta Oncol. 27: 296, 1988.
Sakahara H., Endo K., Saga T., Hosono M., Kobayashi H., Konishi J. 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma. Ann. Nucl. Med. 8: 133, 1994.
Nakagami Y., Nomura K., Kusakabe K., Miko N., Tsushima T., Demura H. A case of malignant pheochromocytoma treated with 131I-metaiodobenzylguanidine and alpha-methyl-p-tyrosine. Jpn. J. Med. 29: 329, 1990.
Sasaki M., Iwaoka T., Yamauchi J., Tokunaga H., Naomi S., Inoue J., Oishi S., Umeda T., Sato T. A case of Sipple’s syndrome with malignant pheochromocytoma treated with 131I-metaiodobenzyl guanidine and a combined chemotherapy with cyclophosphamide, incristine and dacarbazine. Endocr. J. 41: 155, 1994.
Guo J.Z., Gong L.S., Chen S.X., Luo B.Y., Xu M.Y. Malignant pheochromocytoma: diagnosis and treatment in fifteen cases. J. Hypertens. 7: 261, 1989.
Hoefnagel C.A., Voute P.A., de Kraker J., Marcuse H.R. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J.Nucl. Med. 28: 308, 1987.
Beierwaltes W.H. Update on basic research and clinical experience with metaiodobenzylguanidine. Med. Pediatr. Oncol. 15: 163, 1987.
Mastrangelo R., Lasorella A., Iavarone A., Rufini V., Troncone L., Danza F., Riccardi R. Critical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis. Med. Pediatr. Oncol, 21: 411, 1993.
Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47: 207, 1981.
Hoefnagel C.A. Radionuclide therapy revisited. Eur. J. Nucl. Med. 18: 408, 1991.
Koral K.F., Wang X.H., Sisson J.C., Botti J., Meyer L., Mallette S., Glazer G.M., Adler R.S. Calculating radiation absorbed dose for pheochromocytoma tumors in 131ImIBG therapy. J. Rad. Oncol. Biol. 17: 211, 1989.
Vaidyanathan G., Zalutsky M.R. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Appl Radiat Isot (Int. J. Rad. Appl Instrum. [A]. 44: 621, 1993.
Mangner J.T., Wu J.-L., Wieland D.M. Solid-phase exchange radioiodination of aryl iodides: facilitation by ammonium sulfate. J.Org.Chem. 47: 1484, 1982.
Mairs R.J., Cunningham S.H., Russell J., Armour A., Owens J., McKellar K., Gaze M.N. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. J. Nucl. Med. 36: 1088, 1995.
Mairs R.J., Russell J., Cunningham S., O’Donoghue J.A., Gaze M.N., Owens J., Vaidyanathan G., Zalutsky, M.R. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I] meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. Eur. J. Cancer. 31A: 576, 1995.
Sisson J.C., Hutchinson R.J., Carey J.E., Shapiro B., Johnson J.W., Mallette SA, Wieland DM. Toxicity from treatment of neuroblastoma with 131I-metaiodobenzylguanidine. Eur. J. Nucl. Med. 14: 337, 1988.
Blake G.M., Lewington V.J., Fleming J.S., Zivanovic M.A., Ackery D.M. Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant pheochromocytoma. Eur. J. Nucl. Med. 14: 345, 1988.
Khafagi F.A., Shapiro B., Fig L.M., Mallette S., Sisson J.C. Labetalol reduces iodine-131-MIBG uptake by pheochromocytoma and normal tissues. J.Nucl. Med. 30: 481, 1989.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Loh, KC., Fitzgerald, P.A., Matthay, K.K. et al. The treatment of malignant pheochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 20, 648–658 (1997). https://doi.org/10.1007/BF03348026
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348026